Royalty Pharma Reports Q4 and Full Year 2024 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Royalty Pharma (RPRX) Reports Q4 Revenue of $594 million
February 11, 2025 7:54 AM ESTRoyalty Pharma plc (NASDAQ: RPRX) reported Q4 revenue of $594 million, versus $596 million reported last year.
Portfolio Receipts of $742 million in Q4 2024 and $2,801 million for FY 2024Royalty... More